Author

P. Roxburgh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

D. Ennis· 3 shared R. Glasspool· 3 shared A. Ewing· 2 shared A. Matakidou· 2 shared A. Meynert· 2 shared A. V. Biankin· 2 shared B. Dougherty· 2 shared B. McDade· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Ennis

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer

A. Ewing, A. Meynert, R. Silk, S. Aitken, D. P. Bendixsen, M. Churchman, S. L. Brown, A. Hamdan, J. Mattocks, G. R. Grimes, T. Ballinger, R. L. Hollis, C. S. Herrington, J. P. Thomson, K. Sherwood, , C. A. Semple

The paper identifies two divergent structural variation trajectories in HGSOC that impact patient survival and reveals novel candidate driver genes and mtDNA mutations associated with prognosis.

bioRxiv · Jan 12, 2024Cancer Biology

Dual G9A and EZH2 inhibition stimulates an anti-tumour immune response in ovarian high-grade serous carcinoma

P. Spiliopoulou, S. Spear, H. Mirza, I. Garner, L. Mcgarry, F. Grundland-Freile, Z. Cheng, D. Ennis, S. McNamara, M. Natoli, S. Mason, K. Blyth, P. Adams, P. Roxburgh, M. Fuchter, , I. McNeish

This study shows that dual inhibition of G9A and EZH2 in ovarian cancer enhances anti-tumour immune responses by altering the immune microenvironment and reducing tumour growth.

bioRxiv · May 9, 2021Cancer Biology

Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy

G. Y. Ho, E. Kyran, J. Bedo, M. Wakefield, D. Ennis, H. Mirza, S. Cooke, E. Lieschke, C. Vandenberg, O. Kondrashova, R. Upstill-Goddard, U.-M. Bailey, S. Biankin, P. Roxburgh, R. Glasspool, , H. Barker

This study identifies N-MYC pathway activation and susceptibility to EMT-targeting therapy in ovarian carcinosarcoma using genomic and pre-clinical models.

bioRxiv · Nov 24, 2020 · PreprintCancer Biology

Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma

A. Ewing, A. Meynert, M. Churchman, G. R. Grimes, R. L. Hollis, C. S. Herrington, T. Rye, C. Bartos, I. Croy, M. Ferguson, M. Lennie, T. McGoldrick, N. McPhail, N. Siddiqui, S. Dowson, , C. A. Semple

This study identifies large structural variants as a significant source of homologous repair deficiency in high-grade serous ovarian carcinoma, beyond known SNVs and indels at BRCA1/2.

bioRxiv · May 11, 2020Cancer Biology